Year 2025 / Volume 117 / Number 8
Editorial
The Spanish National Strategic Plan for Hepatitis C: A legacy of success

423-425

DOI: 10.17235/reed.2025.11371/2025

Javier Crespo, Agustín Albillos, María Buti,

Abstract
April 2025 marks the 10th anniversary of the Strategic Plan for Addressing Hepatitis C (PEAHC). The inception of PEAHC arose from the necessity to secure funding for the new direct-acting oral antiviral medications to treat hepatitis C in Spain. These drugs had already demonstrated efficacy in clinical trials worldwide and had been approved for use and funding in several European countries. In Spain, however, given the high prevalence of hepatitis C, an intense debate emerged concerning the economic sustainability of implementing these treatments on a large scale, as well as the necessity of prioritizing treatment for patients with the most advanced liver disease. This critical situation triggered an unprecedented collaborative response among individuals living with hepatitis C, healthcare professionals, scientific associations (among which he undoubtedly highlighted the role of the Spanish Association for the Study of the Liver, AEEH), representatives of the National Health System, and the pharmaceutical industry.
New comment
Comments
No comments for this article
References
1. Plan estratégico para el abordaje de la hepatitis C en el Sistema Nacional de Salud. Disponible en: https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/hepatitisC/PlanEstrategicoHEPATITISC/docs/plan_estrategico_hepatitis_C.pdf
2. Crespo J, Cuadrado A, Perelló C, et al. Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain. J Viral Hepat 2020;27(4):360-70. DOI: 10.1111/jvh.13238
3. 2º Estudio de seroprevalencia en España. Disponible en: https://www.sanidad.gob.es/areas/promocionPrevencion/vacunaciones/comoTrabajamos/docs/EstudioSeroprevalencia_EnfermedadesInmunoprevenibles.pdf
4. Crespo J, Albillos A, Buti M, et al. Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). Rev Esp Enferm Dig 2019;111(11):862-73. DOI: 10.17235/reed.2019.6700/2019
5. Rodríguez-Tajes S, Domínguez Á, Carrión JA, et al. Significant decrease in the prevalence of hepatitis C infection after the introduction of direct acting antivirals. J Gastroenterol Hepatol 2020;35(9):1570-8. DOI: 10.1111/jgh.14984
6. Crespo J, Cabezas J, Calleja JL, et al. The path to successful hepatitis C elimination in Spain. Nat Rev Gastroenterol Hepatol 2023;20(11):689-90. DOI: 10.1038/s41575-023-00813-z
7. Rodríguez-Tajes S, Pocurull A, Castillo J, et al. Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025. J Hepatol 2020;73(6):1360-7. DOI: 10.1016/j.jhep.2020.07.018
8. Berenguer M, de la Rosa Rodríguez G, Domínguez-Gil B. Significant impact of new oral therapies against HCV on the waiting list for liver transplantation in Spain. J Hepatol 2018;69(4):966-8. DOI: 10.1016/j.jhep.2018.06.011
9. Vargas-Accarino E, Martínez-Campreciós J, Domínguez-Hernández R, et al. Cost-effectiveness analysis of an active search to retrieve HCV patients lost to follow-up (RELINK-C strategy) and the impact of COVID-19. J Viral Hepat 2022;29(7):579-83. DOI: 10.1111/jvh.13686
10. Mennini FS, Marcellusi A, Robbins Scott S, et al. The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries. Liver Int 2021;41(5):934-48. DOI: 10.1111/liv.14808
11. Gómez de la Cuesta S, Martín-Arribas MI, Mateos Hernández MI, et al. Hepatitis C virus micro-elimination in vulnerable populations before and during a global pandemic. Rev Esp Enferm Dig 2023;115(7):397-8. DOI: 10.17235/reed.2022.9275/2022
12. Cuadrado A, Llerena S, Cobo C, et al. Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm. Am J Gastroenterol 2018;113(11):1639-48. DOI: 10.1038/s41395-018-0157-x
13. Fanciulli C, Berenguer J, Busca C, et al.; GeSIDA 8514 Study Group. Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019. HIV Med 2022;23(7):705-16. DOI: 10.1111/hiv.13229
14. Herranz Mochales A, Picchio CA, Nicolàs A, et al. Implementing a new HCV model of care for people who use drugs. JHEP Rep 2024;6(10):101145. DOI: 10.1016/j.jhepr.2024.101145
15. Guía de cribado de la infección por el VHC. Disponible en: https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/hepatitis/GUIIA_DE_CRIBADO_DE_LA_INFECCION_POR_EL_VHC_2020_rev21-10-2022.pdf
16. Llaneras J, Ruiz-Cobo JC, Rando-Segura A, et al. Integrating viral hepatitis management into the emergency department: A further step towards viral hepatitis elimination. JHEP Rep 2023;6(1):100932. DOI: 10.1016/j.jhepr.2023.100932
17. Alventosa Mateu C, Ocete Mochón MD, Urquijo Ponce JJ, et al. Outcomes of an automated alert system from Microbiology to link diagnosis to treatment in patients with hepatitis C virus. Rev Esp Enferm Dig 2023;115(4):181-7. DOI: 10.17235/reed.2022.8716/2022
18. Crespo J, Calleja JL, Cabezas J, et al. A call for the comprehensive diagnosis of viral hepatitis as a key step towards its elimination. Liver Int 2023;43(5):1145-7. DOI: 10.1111/liv.15529
19. Albertos S, Majo FX, Esteban R, et al. A large-scale screening of hepatitis C among men who have sex with men in the community using saliva point-of-care testing. Front Public Health 2024;12:1478195. DOI: 10.3389/fpubh.2024.1478195
20. Morales-Arráez D, Benítez-Zafra F, Díaz-Flores F, et ak. A slowdown of hepatitis C diagnosis in high-prevalence groups and with decentralized diagnostic strategies during the COVID-19 pandemic. Rev Esp Enferm Dig 2023;115(4):175-80. DOI: 10.17235/reed.2022.8412/2021
21. Calleja JL, Aguilera A, Buti M, et al. Ten steps to eliminating hepatitis C in hospitals. Nat Rev Gastroenterol Hepatol 2022;19(8):481-3. DOI: 10.1038/s41575-022-00647-1
22. Valencia J, Alvaro-Meca A, Troya J, et al. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units. Int J Drug Policy 2019;72:181-8. DOI: 10.1016/j.drugpo.2019.06.016
23. AEHVE. Alianza para la Eliminación de las Hepatitis Víricas en España. Disponible en: https://aehve.org
24. Cabezas J, Crespo J, Aguilera A, et al. Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver. Rev Esp Enferm Dig 2023;115(3):128-32. DOI: 10.17235/reed.2022.9325/2022
Related articles

Editorial

Early liver transplantation in severe alcohol-associated hepatitis

DOI: 10.17235/reed.2024.10881/2024

Letter

Autoimmune hepatitis after COVID-19 infection

DOI: 10.17235/reed.2024.10532/2024

Letter

Fatal HBV-liver failure after withdrawal of antiviral treatment

DOI: 10.17235/reed.2024.10115/2023

Letter

Drug-induced liver injury associated to red yeast rice

DOI: 10.17235/reed.2023.9797/2023

Letter

Hepatitis B virus reactivation after ibrutinib treatment

DOI: 10.17235/reed.2023.9587/2023

Letter

Autoimmune hepatitis after SARS-C¬¬oV-2 vaccination

DOI: 10.17235/reed.2023.9579/2023

Editorial

New actors come into play against hepatitis delta

DOI: 10.17235/reed.2022.9050/2022

Letter

DRESS syndrome secondary to carbamazepine

DOI: 10.17235/reed.2022.8977/2022

Letter

COVID-19 vaccine and autoimmune hepatitis

DOI: 10.17235/reed.2022.8837/2022

Editorial

Orthohepevirus C as causal agent of acute hepatitis in Spain

DOI: 10.17235/reed.2022.8993/2022

Letter

SARS-CoV-2 vaccine, a new autoimmune hepatitis trigger?

DOI: 10.17235/reed.2022.8820/2022

Letter

Cefditoren-induced hepatitis

DOI: 10.17235/reed.2022.8801/2022

Letter

AMA-positive hepatitis induced by the SARS-CoV-2 vaccine.

DOI: 10.17235/reed.2022.8533/2021

Letter

A case of COVID-19 with concomitant infection with hepatitis A

DOI: 10.17235/reed.2021.8372/2021

Editorial

Cases of liver disease lost in the health system: a call to action

DOI: 10.17235/reed.2021.8316/2021

Original

Active search for hepatitis C patients in primary care

DOI: 10.17235/reed.2021.8067/2021

Letter

Autoimmune hepatitis triggered by COVID-19

DOI: 10.17235/reed.2021.8045/2021

Digestive Diseases Image

Emphysematous hepatitis: a very rare entity with a poor prognosis

DOI: 10.17235/reed.2021.7795/2021

Original

Hepatitis C in homeless people: reaching a hard-to-reach population

DOI: 10.17235/reed.2021.7737/2020

Editorial

Screening guide for hepatitis C virus infection in Spain

DOI: 10.17235/reed.2020.7728/2020

Letter

Acute hepatitis due to olmesartan: an uncommon entity

DOI: 10.17235/reed.2020.7236/2020

Special Article

Strategy for the Elimination of Hepatitis C in Cantabria

DOI: 10.17235/reed.2020.7108/2020

Editorial

Reflex testing. A key tool for the elimination of hepatitis C

DOI: 10.17235/reed.2020.7201/2020

Letter

Candesartan-induced cholestatic hepatitis: a case report

DOI: 10.17235/reed.2020.6988/2020

Original

A new pattern in hepatitis A virus infection in an urban population

DOI: 10.17235/reed.2020.6526/2019

Original

Quality of life study in asymptomatic patients with hepatitis C

DOI: 10.17235/reed.2019.6339/2019

Letter

Acute seronegative hepatitis C: two case reports

DOI: 10.17235/reed.2019.5921/2018

Case Report

Sarcoidosis onset simulating a unique hepatic metastasis

DOI: 10.17235/reed.2018.5553/2018

Letter to the Editor

Autoimmune hepatitis as a complication of common variable immunodeficiency

DOI: 10.17235/reed.2018.5280/2017

Letter to the Editor

The clinical challenge of chronic Q fever with isolated liver involvement

DOI: 10.17235/reed.2017.4633/2016

Case Report

The clinical extremes of autoimmune cholangitis

DOI: 10.17235/reed.2017.4167/2015

Case Report

Glycogenic hepatopathy in young adults: a case series

DOI: 10.17235/reed.2016.3934/2015

Citation tools
Crespo J, Albillos A, Buti M. The Spanish National Strategic Plan for Hepatitis C: A legacy of success. 11371/2025


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 12 visits.
This article has been downloaded 0 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 28/05/2025

Accepted: 28/05/2025

Online First: 10/07/2025

Published: 24/07/2025

Article Online First time: 43 days

Article editing time: 57 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2025 y Creative Commons. The Spanish Journal of Gastroenterology